| ASCO/CAP | American Society of Clinical Oncology/College of American Pathologists | |
| ACOSOG | American College of Surgeons Oncology Group | |
| ACR | American College of Radiology | 米国放射線専門医会 |
| ALND | axillary lymph node dissection | 腋窩リンパ節郭清 |
| AOR | annual odds of recurrence | 年間再発率 |
| APBI | accelerated partial breast irradiation | 加速乳房部分照射 |
| ASA | American Society of Anesthesiologists | 米国麻酔科学会 |
| ASCO | American Society of Clinical Oncology | 米国臨床腫瘍学会 |
| ASTRO | American Society for Radiation Oncology | 米国放射線腫瘍学会 |
| BMD | bone mineral density | 骨密度 |
| BMI | body mass index | |
| BOOP | bronchiolitis obliterans organizing pneumonia | |
| CALGB | Cancer and Leukemia Group B | |
| CAM | complementary and alternative medicine | 補完・代替療法 |
| CBR | clinical benefit rate | クリニカルベネフィット率 |
| CI | confidence interval | 信頼区間 |
| CIA | chemotherapy‒induced amenorrhea | 化学療法誘発性無月経 |
| CR | complete response | 完全奏効 |
| CTV | clinical target volume | 臨床標的体積 |
| DBCG | Danish Breast Cancer Cooperative Group | |
| DCIS | ductal carcinoma in situ | 非浸潤性乳管癌 |
| DFI | disease‒free interval | 無病生存期間 |
| DFS | disease‒free survival | 無病生存期間,無病生存率 |
| EBCTCG | Early Breast Cancer Trialists’ Collaborative Group | |
| EBM | evidence-based medicine | 根拠に基づく医療 |
| ECOG | Eastern Cooperative Oncology Group | |
| EFS | event‒free survival | 無イベント生存率 |
| EIC | extensive intraductal component | 広範な乳管内進展 |
| EMLA | eutectic mixture of local anesthetics | |
| EORTC | European Organization for Research and Treatment of Cancer | |
| EORTC QLQ | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire | |
| ER | estrogen receptor | エストロゲン受容体 |
| FACT | Functional Assessment of Cancer Therapy | |
| FDA | Food and Drug Administration | 米国食品医薬品局 |
| FSH | follicle stimulating hormone | 卵胞(濾胞)刺激ホルモン |
| G―CSF | granulocyte―colony stimulating factor | 顆粒球コロニー刺激因子 |
| GPA | graded prognostic assessment | |
| GTV | gross tumor volume | 肉眼的腫瘍体積 |
| HER2 | human epidermal growth factor receptor type 2 | ヒト上皮増殖因子受容体2型 |
| HR | hazard ratio | ハザード比 |
| HRD | homologous recombination deficiency | 相同組み換え修復不全 |
| IBCSG | International Breast Cancer Study Group | |
| ICG | indocyanine green | インドシアニングリーン |
| IDFS | invasive disease‒free survival | 浸潤癌の無病生存期間 |
| IHC | immunohistochemical staining | 免疫組織化学的方法 |
| IMRT | intensity modulated radiation therapy | 強度変調放射線治療 |
| IPC | intermittent pneumatic compression | 間歇的空気圧迫療法 |
| ITC | isolated tumor cells | 遊離腫瘍細胞 |
| JCOG | Japan Clinical Oncology Group | 日本臨床腫瘍研究グループ |
| LLLT | low level laser therapy | 低出力レーザー療法 |
| LVEF | left ventricular ejection fraction | 左室駆出率 |
| NAC | neoadjuvant chemotherapy | 術前化学療法 |
| NCCAM | National Center for Complementary and Alternative Medicine | 米国国立代替医療センター |
| NCCN | National Comprehensive Cancer Network | 全米総合がん情報ネットワーク |
| NCI | National Cancer Institute | 米国国立癌研究所 |
| NSABP | National Surgical Adjuvant Breast and Bowel Project | |
| NSAIDs | non―steroidal anti―inflammatory drugs | 非ステロイド消炎鎮痛薬 |
| N―SAS BC | National Surgical Adjuvant Study of Breast Cancer | |
| NSM | nipple―sparing mastectomy | 乳頭温存乳房全切除術 |
| OBS | oncoplastic breast surgery | 乳房オンコプラスティックサージャリー |
| ONJ | osteonecrosis of the jaw | 顎骨壊死 |
| OR | odds ratio | オッズ比 |
| ORR | overall response rate | 全奏効割合,全奏効率 |
| OS | overall survival | 全生存期間,全生存率 |
| PARP | poly(ADP―ribose)polymerase | ポリADPリボースポリメラーゼ |
| pCR | pathological complete response | 病理学的完全奏効 |
| PD | progressive disease | 進行 |
| PFS | progression free survival | 無増悪生存期間,無増悪生存率 |
| PgR | progesterone receptor | プロゲステロン受容体 |
| PMDA | Pharmaceutical and Medical Devices Agency | 医薬品医療機器総合機構 |
| PMPS | postmastectomy pain syndrome | 乳房切除後疼痛症候群 |
| PMRT | postmastectomy radiation therapy | 乳房切除術後放射線療法 |
| PPS | post‒progression survival | 初回治療後の増悪後の生存期間 |
| PS | performance status | パフォーマンスステータス |
| PTV | planning target volume | 計画標的体積 |
| QOL | quality of life | 生活の質 |
| QOL‒ACD | Quality of Life Questionnaire for Cancer Patients Targeted with American Drugs | |
| RANKL | receptor activator of nuclear factor κ―B ligand | |
| RCT | randomized controlled trial | ランダム化比較試験 |
| RFA | radiofrequency ablation | ラジオ波熱凝固療法 |
| RFS | relapse―free survival,recurrence―free survival | 無再発生存期間,無再発生存率 |
| RI | radioisotope | ラジオアイソトープ |
| RR | rate ratio | レート比 |
| RR | risk ratio | リスク比 |
| RS | recurrence score | |
| RTOG | Radiation Therapy Oncology Group | 米国腫瘍放射線治療グループ |
| RT‒PCR | reverse transcription polymerase chain reaction | |
| SD | stable disease | |
| SE | standard error | 標準誤差 |
| SEER | Surveillance, Epidemiology and End Results | |
| SERM | selective estrogen receptor modulator | 選択的エストロゲン受容体モジュレーター |
| SLE | systemic lupus erythematosus | 全身性エリテマトーデス |
| SLN | sentinel lymph node | センチネルリンパ節 |
| SNB | sentinel node biopsy | センチネルリンパ節生検 |
| SRE | skeletal―related event | 骨関連事象 |
| SRS | stereotactic radiosurgery | 定位手術的照射 |
| SRT | stereotactic radiotherapy | 定位[的]放射線治療 |
| SSI | surgical site infection | 手術部位感染 |
| SSM | skin―sparing mastectomy | 皮膚温存乳房全切除術 |
| SSO | Society of Surgical Oncology | |
| SSRI | selective serotonin reuptake inhibitor | 選択的セロトニン再取込み阻害薬 |
| STI | stereotactic irradiation | 定位放射線照射 |
| SWOG | Southwest Oncology Group | |
| TE | tissue expander | 組織拡張器 |
| TNBC | triple negative breast cancer | トリプルネガティブ乳癌 |
| TPC | treatment of physician’s choice | |
| TTF | time to treatment failure | 治療成功期間 |
| TTP | time to progression | 無増悪期間,病勢進行までの期間 |
| VATS | video―assisted thoracic surgery | 胸腔鏡手術 |
| VEGF | vascular endothelial growth factor | 血管内皮増殖因子 |
| VNPI | Van Nuys prognostic index | |
| WHO | World Health Organization | 世界保健機関 |
| YAM | young adult mean | 若年成人平均値 |

